The identification of acute HCV infection has been a major challenge throughout the years as its natural course is usually silent and asymptomatic. Collaborative efforts are being made throughout the worid to recognize new cases as they offer relevant information on viral and host interactions. This continued project has already identified 77 cases of acute HCV infection;most of which were symptomatic (80%), and with risk factors being mainly nosocomial in medical settings followed by sexual transmission. Spontaneous clearance was documented in 54%. and most cases were due to a single exposure as there were no reports of intravenous drug use. Even though patients were referred to hepatitis treatment centers as eariy as 3 months, a number of patients were not treated during the acute phase, and we were, surprisingly able to observe delayed spontaneous clearance in a few. Subjects adhered highly to the study and results have been obtained through a follow-up of pafients during a course of almost 9 years, with a high yield of sequenfial and serial bank specimens. This study will not only help identify HCV in the eariy phase of infecfion but also offer confinued long fime serial samples for further studies on immune pathogenesis for future development of successful immunotherapeutic intervenfions and vaccines.

Public Health Relevance

This core will provide long term follow-up samples critical for science projects to help understand the immune pathogenesis of HCV infection which will further assist in the identification of novel antiviral agents and development of efficacious vaccines.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI066345-09
Application #
8495878
Study Section
Special Emphasis Panel (ZAI1-BP-M)
Project Start
Project End
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
9
Fiscal Year
2013
Total Cost
$149,007
Indirect Cost
$56,827
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Torres-Cornejo, Almudena; Lauer, Georg M (2017) Hurdles to the Development of Effective HBV Immunotherapies and HCV Vaccines. Pathog Immun 2:102-125
Wolski, David; Foote, Peter K; Chen, Diana Y et al. (2017) Early Transcriptional Divergence Marks Virus-Specific Primary Human CD8+ T Cells in Chronic versus Acute Infection. Immunity 47:648-663.e8
Rodrigo, Chaturaka; Walker, Melanie R; Leung, Preston et al. (2017) Limited naturally occurring escape in broadly neutralizing antibody epitopes in hepatitis C glycoprotein E2 and constrained sequence usage in acute infection. Infect Genet Evol 49:88-96
Rodrigo, C; Eltahla, A A; Bull, R A et al. (2017) Phylogenetic analysis of full-length, early infection, hepatitis C virus genomes among people with intravenous drug use: the InC3 Study. J Viral Hepat 24:43-52
Vergara, C; Thio, C; Latanich, R et al. (2017) Genetic basis for variation in plasma IL-18 levels in persons with chronic hepatitis C virus and human immunodeficiency virus-1 infections. Genes Immun 18:82-87
Rodrigo, Chaturaka; Eltahla, Auda A; Bull, Rowena A et al. (2016) Historical Trends in the Hepatitis C Virus Epidemics in North America and Australia. J Infect Dis 214:1383-1389
Page, Kimberly; Mirzazadeh, Ali; Rice, Thomas M et al. (2016) Interferon Lambda 4 Genotype Is Associated With Jaundice and Elevated Aminotransferase Levels During Acute Hepatitis C Virus Infection: Findings From the InC3 Collaborative. Open Forum Infect Dis 3:ofw024
Gunn, Bronwyn; Schneider, Jeffrey; Shansab, Maryam et al. (2016) Enhanced binding of antibodies generated during chronic HIV infection to mucus component MUC16. Mucosal Immunol 9:1549-1558
Doyle, J S; Deterding, K; Grebely, J et al. (2015) Response to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort. J Viral Hepat 22:1020-32
Sacks-Davis, Rachel; Grebely, Jason; Dore, Gregory J et al. (2015) Hepatitis C Virus Reinfection and Spontaneous Clearance of Reinfection--the InC3 Study. J Infect Dis 212:1407-19

Showing the most recent 10 out of 55 publications